Allogeneic peripheral-blood progenitor-cell transplantation for poor- risk patients with metastatic breast cancer

Naoto T. Ueno, Gabriela Rondón, Nadeem Q. Mirza, Deborah K. Geisler, Paolo Anderlini, Sergio A. Giralt, Borje S. Andersson, David F. Claxton, James L. Gajewski, Issa F. Khouri, Martin Körbling, Rakesh C. Mehra, Donna Przepiorka, Zia Rahman, Barry I. Samuels, Koen Van Besien, Gabriel N. Hortobagyi, Richard E. Champlin

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

Purpose: To evaluate the feasibility of allegeneic peripheral-blood progenitor-cell (PBPC) transplantation and to assess graft-versus-tumor effects in patients with metastatic breast cancer. Patients and Methods: Ten patients with metastatic breast cancer that involved the liver or bone marrow were treated with high-dose chemotherapy and allogeneic PBPC transplantation. The median age was 42 years (range, 29 to 55). The median number of metastatic sites was three (range, one to five). The conditioning regimen was cyclophosphamide (6,000 mg/m2), carmustine (BCNU; 450 mg/m2), and thiotepa (720 mg/m2) (CBT regimen). Patients received graft-versus-host disease (GVHD) prophylaxis using cyclosporine- or tacrolimus-based regimens. Results: All patients had engraftment and hematologic recovery. Three patients developed grade ≤ 2 acute GVHD and four patients had chronic GVHD. After transplantation, one patient was in complete remission (CR), five achieved a partial remission (PR), and four had stable disease (SD). In two patients, metastatic liver lesions regressed in association with skin GVHD after withdrawal of immunosuppressive therapies. The median follow-up time was 408 days (range, 53 to 605). The median progression-free survival duration was 238 days (range, 53 to 510). Conclusion: We conclude that allogeneic PBPC transplantation is a feasible procedure for patients with poor-risk metastatic breast cancer. The regression of tumor associated with GVHD provides suggestive clinical evidence that graft-versus-tumor effects may occur against breast cancer. Compared with autologous transplantation, allogeneic PBPC transplantation is associated with the additional risks of GVHD and related infections. Allogeneic transplantation should only be performed in the context of clinical trials and its ultimate role requires demonstration of improved progression-free survival.

Original languageEnglish (US)
Pages (from-to)986-993
Number of pages8
JournalJournal of Clinical Oncology
Volume16
Issue number3
StatePublished - Mar 1998
Externally publishedYes

Fingerprint

Cell Transplantation
Blood Cells
Stem Cells
Breast Neoplasms
Graft vs Host Disease
Carmustine
Disease-Free Survival
Thiotepa
Transplants
Bone Neoplasms
Neoplasms
Autologous Transplantation
Homologous Transplantation
Tacrolimus
Liver Neoplasms
Immunosuppressive Agents
Cyclophosphamide
Cyclosporine
Transplantation
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ueno, N. T., Rondón, G., Mirza, N. Q., Geisler, D. K., Anderlini, P., Giralt, S. A., ... Champlin, R. E. (1998). Allogeneic peripheral-blood progenitor-cell transplantation for poor- risk patients with metastatic breast cancer. Journal of Clinical Oncology, 16(3), 986-993.

Allogeneic peripheral-blood progenitor-cell transplantation for poor- risk patients with metastatic breast cancer. / Ueno, Naoto T.; Rondón, Gabriela; Mirza, Nadeem Q.; Geisler, Deborah K.; Anderlini, Paolo; Giralt, Sergio A.; Andersson, Borje S.; Claxton, David F.; Gajewski, James L.; Khouri, Issa F.; Körbling, Martin; Mehra, Rakesh C.; Przepiorka, Donna; Rahman, Zia; Samuels, Barry I.; Van Besien, Koen; Hortobagyi, Gabriel N.; Champlin, Richard E.

In: Journal of Clinical Oncology, Vol. 16, No. 3, 03.1998, p. 986-993.

Research output: Contribution to journalArticle

Ueno, NT, Rondón, G, Mirza, NQ, Geisler, DK, Anderlini, P, Giralt, SA, Andersson, BS, Claxton, DF, Gajewski, JL, Khouri, IF, Körbling, M, Mehra, RC, Przepiorka, D, Rahman, Z, Samuels, BI, Van Besien, K, Hortobagyi, GN & Champlin, RE 1998, 'Allogeneic peripheral-blood progenitor-cell transplantation for poor- risk patients with metastatic breast cancer', Journal of Clinical Oncology, vol. 16, no. 3, pp. 986-993.
Ueno NT, Rondón G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor- risk patients with metastatic breast cancer. Journal of Clinical Oncology. 1998 Mar;16(3):986-993.
Ueno, Naoto T. ; Rondón, Gabriela ; Mirza, Nadeem Q. ; Geisler, Deborah K. ; Anderlini, Paolo ; Giralt, Sergio A. ; Andersson, Borje S. ; Claxton, David F. ; Gajewski, James L. ; Khouri, Issa F. ; Körbling, Martin ; Mehra, Rakesh C. ; Przepiorka, Donna ; Rahman, Zia ; Samuels, Barry I. ; Van Besien, Koen ; Hortobagyi, Gabriel N. ; Champlin, Richard E. / Allogeneic peripheral-blood progenitor-cell transplantation for poor- risk patients with metastatic breast cancer. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 3. pp. 986-993.
@article{002fee0e37ca4040a5512f4337d69a04,
title = "Allogeneic peripheral-blood progenitor-cell transplantation for poor- risk patients with metastatic breast cancer",
abstract = "Purpose: To evaluate the feasibility of allegeneic peripheral-blood progenitor-cell (PBPC) transplantation and to assess graft-versus-tumor effects in patients with metastatic breast cancer. Patients and Methods: Ten patients with metastatic breast cancer that involved the liver or bone marrow were treated with high-dose chemotherapy and allogeneic PBPC transplantation. The median age was 42 years (range, 29 to 55). The median number of metastatic sites was three (range, one to five). The conditioning regimen was cyclophosphamide (6,000 mg/m2), carmustine (BCNU; 450 mg/m2), and thiotepa (720 mg/m2) (CBT regimen). Patients received graft-versus-host disease (GVHD) prophylaxis using cyclosporine- or tacrolimus-based regimens. Results: All patients had engraftment and hematologic recovery. Three patients developed grade ≤ 2 acute GVHD and four patients had chronic GVHD. After transplantation, one patient was in complete remission (CR), five achieved a partial remission (PR), and four had stable disease (SD). In two patients, metastatic liver lesions regressed in association with skin GVHD after withdrawal of immunosuppressive therapies. The median follow-up time was 408 days (range, 53 to 605). The median progression-free survival duration was 238 days (range, 53 to 510). Conclusion: We conclude that allogeneic PBPC transplantation is a feasible procedure for patients with poor-risk metastatic breast cancer. The regression of tumor associated with GVHD provides suggestive clinical evidence that graft-versus-tumor effects may occur against breast cancer. Compared with autologous transplantation, allogeneic PBPC transplantation is associated with the additional risks of GVHD and related infections. Allogeneic transplantation should only be performed in the context of clinical trials and its ultimate role requires demonstration of improved progression-free survival.",
author = "Ueno, {Naoto T.} and Gabriela Rond{\'o}n and Mirza, {Nadeem Q.} and Geisler, {Deborah K.} and Paolo Anderlini and Giralt, {Sergio A.} and Andersson, {Borje S.} and Claxton, {David F.} and Gajewski, {James L.} and Khouri, {Issa F.} and Martin K{\"o}rbling and Mehra, {Rakesh C.} and Donna Przepiorka and Zia Rahman and Samuels, {Barry I.} and {Van Besien}, Koen and Hortobagyi, {Gabriel N.} and Champlin, {Richard E.}",
year = "1998",
month = "3",
language = "English (US)",
volume = "16",
pages = "986--993",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Allogeneic peripheral-blood progenitor-cell transplantation for poor- risk patients with metastatic breast cancer

AU - Ueno, Naoto T.

AU - Rondón, Gabriela

AU - Mirza, Nadeem Q.

AU - Geisler, Deborah K.

AU - Anderlini, Paolo

AU - Giralt, Sergio A.

AU - Andersson, Borje S.

AU - Claxton, David F.

AU - Gajewski, James L.

AU - Khouri, Issa F.

AU - Körbling, Martin

AU - Mehra, Rakesh C.

AU - Przepiorka, Donna

AU - Rahman, Zia

AU - Samuels, Barry I.

AU - Van Besien, Koen

AU - Hortobagyi, Gabriel N.

AU - Champlin, Richard E.

PY - 1998/3

Y1 - 1998/3

N2 - Purpose: To evaluate the feasibility of allegeneic peripheral-blood progenitor-cell (PBPC) transplantation and to assess graft-versus-tumor effects in patients with metastatic breast cancer. Patients and Methods: Ten patients with metastatic breast cancer that involved the liver or bone marrow were treated with high-dose chemotherapy and allogeneic PBPC transplantation. The median age was 42 years (range, 29 to 55). The median number of metastatic sites was three (range, one to five). The conditioning regimen was cyclophosphamide (6,000 mg/m2), carmustine (BCNU; 450 mg/m2), and thiotepa (720 mg/m2) (CBT regimen). Patients received graft-versus-host disease (GVHD) prophylaxis using cyclosporine- or tacrolimus-based regimens. Results: All patients had engraftment and hematologic recovery. Three patients developed grade ≤ 2 acute GVHD and four patients had chronic GVHD. After transplantation, one patient was in complete remission (CR), five achieved a partial remission (PR), and four had stable disease (SD). In two patients, metastatic liver lesions regressed in association with skin GVHD after withdrawal of immunosuppressive therapies. The median follow-up time was 408 days (range, 53 to 605). The median progression-free survival duration was 238 days (range, 53 to 510). Conclusion: We conclude that allogeneic PBPC transplantation is a feasible procedure for patients with poor-risk metastatic breast cancer. The regression of tumor associated with GVHD provides suggestive clinical evidence that graft-versus-tumor effects may occur against breast cancer. Compared with autologous transplantation, allogeneic PBPC transplantation is associated with the additional risks of GVHD and related infections. Allogeneic transplantation should only be performed in the context of clinical trials and its ultimate role requires demonstration of improved progression-free survival.

AB - Purpose: To evaluate the feasibility of allegeneic peripheral-blood progenitor-cell (PBPC) transplantation and to assess graft-versus-tumor effects in patients with metastatic breast cancer. Patients and Methods: Ten patients with metastatic breast cancer that involved the liver or bone marrow were treated with high-dose chemotherapy and allogeneic PBPC transplantation. The median age was 42 years (range, 29 to 55). The median number of metastatic sites was three (range, one to five). The conditioning regimen was cyclophosphamide (6,000 mg/m2), carmustine (BCNU; 450 mg/m2), and thiotepa (720 mg/m2) (CBT regimen). Patients received graft-versus-host disease (GVHD) prophylaxis using cyclosporine- or tacrolimus-based regimens. Results: All patients had engraftment and hematologic recovery. Three patients developed grade ≤ 2 acute GVHD and four patients had chronic GVHD. After transplantation, one patient was in complete remission (CR), five achieved a partial remission (PR), and four had stable disease (SD). In two patients, metastatic liver lesions regressed in association with skin GVHD after withdrawal of immunosuppressive therapies. The median follow-up time was 408 days (range, 53 to 605). The median progression-free survival duration was 238 days (range, 53 to 510). Conclusion: We conclude that allogeneic PBPC transplantation is a feasible procedure for patients with poor-risk metastatic breast cancer. The regression of tumor associated with GVHD provides suggestive clinical evidence that graft-versus-tumor effects may occur against breast cancer. Compared with autologous transplantation, allogeneic PBPC transplantation is associated with the additional risks of GVHD and related infections. Allogeneic transplantation should only be performed in the context of clinical trials and its ultimate role requires demonstration of improved progression-free survival.

UR - http://www.scopus.com/inward/record.url?scp=0031911005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031911005&partnerID=8YFLogxK

M3 - Article

C2 - 9508181

AN - SCOPUS:0031911005

VL - 16

SP - 986

EP - 993

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -